Physician profile
Donna Henry
NPI 1881706943
$16,051.05
in general payments reported to CMS, 2019-2025
30 companies · $2,404 in 2025
The $2,404 reported for 2025 was more than what 91% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $1,264 · 2021: $3,452 · 2022: $1,811 · 2023: $2,712 · 2024: $2,920 · 2025: $2,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,811 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,811.20 |
| Education | $225.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,969.46 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $2,588.05 | 2019-2025 | Epclusa, Vemlidy, Biktarvy |
| Janssen Products, LP | $2,110.14 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,893.14 | 2019-2025 | |
| Astellas Pharma US INC | $1,042.85 | 2019-2025 | Veozah, Myrbetriq, Vesicare |
| Daiichi Sankyo INC. | $529.09 | 2020-2022 | |
| Theratechnologies INC. | $470.82 | 2021-2025 | Trogarzo, Egrifta |
| Paratek Pharmaceuticals, INC. | $367.65 | 2024-2025 | Nuzyra |
| Therapeuticsmd, INC. | $259.59 | 2019-2022 | |
| Pfizer INC. | $214.04 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $190.29 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $170.27 | 2021-2022 | |
| Evofem Biosciences, INC. | $167.12 | 2021-2023 | Phexxi |
| Sumitomo Pharma America, INC. | $158.78 | 2023-2025 | Gemtesa, Myfembree |
| Myovant Sciences INC. | $136.43 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $125.00 | 2023 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $96.66 | 2019 | |
| Sage Therapeutics, LLC | $96.65 | 2020 | |
| Shield Therapeutics INC | $73.71 | 2023 | Accrufer |
| Organon LLC | $70.31 | 2022-2023 | Nexplanon |
| Agile Therapeutics, INC. | $67.72 | 2021-2023 | Twirla |
| Amag Pharmaceuticals, INC. | $53.38 | 2019 | |
| Coopersurgical, INC. | $43.02 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Avion Pharmaceuticals | $41.60 | 2020-2022 | |
| Amgen INC. | $36.08 | 2019 | |
| Duchesnay USA Incorporated | $23.85 | 2019 | |
| Hologic Sales and Service, LLC | $18.13 | 2020 | |
| Gen-Probe, INC. | $12.80 | 2020 | |
| Millicent US INC | $12.66 | 2020 | |
| Allergan, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.